Xenon Pharmaceuticals Inc. NASDAQ:XENE

Xenon Pharmaceuticals stock price today

$37.36
-1.46
-3.79%
Financial Health
0
1
2
3
4
5
6
7
8
9

Xenon Pharmaceuticals stock price monthly change

-9.53%
month

Xenon Pharmaceuticals stock price quarterly change

-9.53%
quarter

Xenon Pharmaceuticals stock price yearly change

-16.42%
year

Xenon Pharmaceuticals key metrics

Market Cap
2.90B
Enterprise value
N/A
P/E
-17.01
EV/Sales
-4.73
EV/EBITDA
0.52
Price/Sales
0.22
Price/Book
N/A
PEG ratio
1.03
EPS
-2.71
Revenue
N/A
EBITDA
-222.59M
Income
-188.59M
Revenue Q/Q
N/A
Revenue Y/Y
694.95%
Profit margin
-932.94%
Oper. margin
-909.22%
Gross margin
0%
EBIT margin
-909.22%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Xenon Pharmaceuticals stock price history

Xenon Pharmaceuticals stock forecast

Xenon Pharmaceuticals financial statements

Average Price Target
Last Year

$50.67

Potential upside: 35.61%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Profit margin
Jun 2023 0 -47.46M
Sep 2023 0 -48.46M
Dec 2023 5.38M -44.74M -831.65%
Mar 2024 0 -47.93M
Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Debt to assets
Jun 2023 684899000 38.44M 5.61%
Sep 2023 671093000 34.50M 5.14%
Dec 2023 964798000 36.87M 3.82%
Mar 2024 919023000 31.32M 3.41%
Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Cash Flow
Jun 2023 -33.22M 27.90M 0
Sep 2023 -42.23M 48.03M 29.50M
Dec 2023 -33.68M -239.18M 320.69M
Mar 2024 -43.17M -46.20M 0

Xenon Pharmaceuticals alternative data

Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Employee count
Aug 2023 203
Sep 2023 203
Oct 2023 203
Nov 2023 203
Dec 2023 203
Jan 2024 203
Feb 2024 203
Mar 2024 251
Apr 2024 251
May 2024 251
Jun 2024 251
Jul 2024 251

Xenon Pharmaceuticals other data

100.00% 0.00%
of XENE is owned by hedge funds
49.18M +1.53M
shares is hold by hedge funds

Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Insider trades (number of shares)
Period Buy Sel
Mar 2024 0 22229
Nov 2024 0 4891
Dec 2024 0 18709
Transaction Date Insider Security Shares Price per share Total value Source
Option
AULIN SHERRY officer: Chief Financial Officer
Common Shares 16,000 $11.58 $185,280
Option
AULIN SHERRY officer: Chief Financial Officer
Common Shares 9,334 $9.44 $88,113
Option
AULIN SHERRY officer: Chief Financial Officer
Stock Option (Right to Buy) 16,000 $11.58 $185,280
Sale
AULIN SHERRY officer: Chief Financial Officer
Common Shares 18,709 $41.21 $770,998
Option
AULIN SHERRY officer: Chief Financial Officer
Stock Option (Right to Buy) 9,334 $9.44 $88,113
Option
PATOU GARY director
Common Shares 3,500 $7.38 $25,830
Option
PATOU GARY director
Common Shares 3,086 $13.48 $41,599
Sale
PATOU GARY director
Common Shares 4,891 $41.08 $200,922
Option
PATOU GARY director
Stock Option (Right to Buy) 6,586 $10.43 $68,692
Option
GAROFALO ELIZABETH A. director
Stock Option (Right to Buy) 3,500 $18.56 $64,960
Patent
Application
Filling date: 9 Feb 2022 Issue date: 25 Aug 2022
Application
Filling date: 22 Nov 2021 Issue date: 23 Jun 2022
Grant
Filling date: 13 Jul 2020 Issue date: 10 May 2022
Grant
Filling date: 28 Jul 2020 Issue date: 12 Apr 2022
Application
Filling date: 1 Oct 2021 Issue date: 3 Mar 2022
Application
Filling date: 6 Jul 2021 Issue date: 3 Mar 2022
Application
Filling date: 6 Aug 2021 Issue date: 24 Feb 2022
Grant
Filling date: 3 Sep 2020 Issue date: 21 Dec 2021
Grant
Filling date: 2 Mar 2020 Issue date: 16 Nov 2021
Grant
Filling date: 3 Dec 2019 Issue date: 19 Oct 2021
Insider Compensation
Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D. (1968) Executive Chairman
$787,780
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA (1976) Pres, Chief Executive Officer & Director
$667,550
Thursday, 12 December 2024
zacks.com
Friday, 6 December 2024
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Wednesday, 13 November 2024
globenewswire.com
zacks.com
Tuesday, 12 November 2024
seekingalpha.com
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Wednesday, 2 October 2024
globenewswire.com
Monday, 9 September 2024
globenewswire.com
Wednesday, 28 August 2024
proactiveinvestors.co.uk
Wednesday, 21 August 2024
zacks.com
Friday, 9 August 2024
seekingalpha.com
zacks.com
Thursday, 8 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Tuesday, 30 July 2024
globenewswire.com
Wednesday, 5 June 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
Friday, 10 May 2024
Zacks Investment Research
Proactive Investors
Wednesday, 8 May 2024
GlobeNewsWire
Proactive Investors
Monday, 6 May 2024
Zacks Investment Research
Wednesday, 10 April 2024
GlobeNewsWire
Thursday, 4 April 2024
GlobeNewsWire
Friday, 1 March 2024
Zacks Investment Research
Wednesday, 21 February 2024
InvestorPlace
Tuesday, 23 January 2024
Zacks Investment Research
Friday, 19 January 2024
Zacks Investment Research
  • What's the price of Xenon Pharmaceuticals stock today?

    One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $37.36.

  • When is Xenon Pharmaceuticals's next earnings date?

    Unfortunately, Xenon Pharmaceuticals's (XENE) next earnings date is currently unknown.

  • Does Xenon Pharmaceuticals pay dividends?

    No, Xenon Pharmaceuticals does not pay dividends.

  • How much money does Xenon Pharmaceuticals make?

    Xenon Pharmaceuticals has a market capitalization of 2.90B.

  • What is Xenon Pharmaceuticals's stock symbol?

    Xenon Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "XENE".

  • What is Xenon Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Xenon Pharmaceuticals?

    Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Xenon Pharmaceuticals's key executives?

    Xenon Pharmaceuticals's management team includes the following people:

    • Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D. Executive Chairman(age: 57, pay: $787,780)
    • Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA Pres, Chief Executive Officer & Director(age: 49, pay: $667,550)
  • How many employees does Xenon Pharmaceuticals have?

    As Jul 2024, Xenon Pharmaceuticals employs 251 workers.

  • When Xenon Pharmaceuticals went public?

    Xenon Pharmaceuticals Inc. is publicly traded company for more then 10 years since IPO on 5 Nov 2014.

  • What is Xenon Pharmaceuticals's official website?

    The official website for Xenon Pharmaceuticals is xenon-pharma.com.

  • Where are Xenon Pharmaceuticals's headquarters?

    Xenon Pharmaceuticals is headquartered at 3650 Gilmore Way, Burnaby, BC.

  • How can i contact Xenon Pharmaceuticals?

    Xenon Pharmaceuticals's mailing address is 3650 Gilmore Way, Burnaby, BC and company can be reached via phone at +1 604 484 3300.

  • What is Xenon Pharmaceuticals stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for Xenon Pharmaceuticals in the last 12 months, the avarage price target is $50.67. The average price target represents a 35.61% change from the last price of $37.36.

Xenon Pharmaceuticals company profile:

Xenon Pharmaceuticals Inc.

xenon-pharma.com
Exchange:

NASDAQ

Full time employees:

251

Industry:

Biotechnology

Sector:

Healthcare

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

3650 Gilmore Way
Burnaby, BC V5G 4W8

CIK: 0001582313
ISIN: CA98420N1050
CUSIP: 98420N105